Disease Overview：Congenital Nephrotic Syndrome（CNS）
Congenital nephrotic syndrome (CNS) is a rare, genetically heterogeneous group of disorders presenting in infancy or early childhood with massive proteinuria, hypoalbuminemia, hyperlipidemia, and severe edema—often within the first three months of life. It results from mutations in genes critical for podocyte structure and function, most commonly NPHS1 (nephrin), NPHS2 (podocin), WT1, or LAMB2. Unlike acquired forms, CNS typically progresses rapidly to end-stage kidney disease without intervention, necessitating early diagnosis via genetic testing, renal biopsy (when clinically indicated), and multidisciplinary management involving pediatric nephrology, genetics, nutrition, and transplant services. Standard care includes aggressive supportive therapy—albumin infusions, ACE inhibitors, anticoagulation—and timely nephrectomy followed by bilateral kidney transplantation, which remains the only curative option for most subtypes.
China offers distinct advantages for international patients seeking CNS management. Leading pediatric nephrology centers—such as those affiliated with Peking University First Hospital and Shanghai Children’s Medical Center—combine deep expertise in rare glomerular diseases with advanced genomic sequencing platforms, real-time intraoperative fluorescence imaging during transplant, and robust post-transplant immunomonitoring protocols. Over 300 successful pediatric kidney transplants for CNS have been reported in China since 2018, with 5-year graft survival exceeding 92% in select cohorts. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards or regulatory oversight. As a dedicated medical tourism agency, we facilitate seamless access: coordinating referrals with certified specialists, verifying hospital accreditation, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and accommodation to interpreter services and post-discharge follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Congenital Nephrotic Syndrome (CNS)
I. Non-Surgical / Conservative / Medication-Based Management *Target criteria:* Confirmed *NPHS1*, *NPHS2*, or *WT1* mutation; proteinuria >3.5 g/day, hypoalbuminemia (<25 g/L), edema; no end-stage renal disease (eGFR ≥30 mL/min/1.73m²).
- •First-line immunosuppression (steroid-sparing):
- Tacrolimus (TDM + genotyping for CYP3A5): ¥2,200–¥3,000/month ($305–$415)
- •Adjunctive therapy:
- High-dose albumin infusions (25% IV, 1 g/kg/d × 3 days/month): ¥480–¥720/course ($66–$100)
- •Essential diagnostics (per 3-month cycle):
- Serum albumin, creatinine, lipid panel, cyclosporine/tacrolimus trough level: ¥320 ($44) - Renal ultrasound + Doppler: ¥260 ($36)
II. Surgical / Procedural / Interventional Options *Eligibility:* eGFR <15 mL/min/1.73m², refractory nephrotic syndrome with recurrent infections/thrombosis, or biopsy-proven FSGS/focal glomerular collapse.
- •Bilateral native nephrectomy + preemptive kidney transplantation:
- Nephrectomy (laparoscopic, bilateral): ¥28,000–¥36,000 ($3,880–$5,000) - Deceased-donor kidney transplant (surgery + 30-day inpatient immunosuppression): ¥198,000–¥245,000 ($27,500–$34,000) - Living-donor transplant (same-day surgery + 30-day care): ¥165,000–¥210,000 ($22,900–$29,200)
III. Special / Complex Condition Management
- •Refractory thrombotic microangiopathy (TMA) with CNS: Plasma exchange (5 sessions, 1.5× plasma volume): ¥12,500 ($1,735)
- •Genotype-guided targeted therapy (e.g., *NPHS2*-associated): Rituximab (375 mg/m² × 4 doses): ¥18,200 ($2,530)
- •Chronic dialysis (peritoneal, pediatric-capable center): ¥4,200/month ($580)
- •Infants (<1 yr), severe edema/infection: Start cyclosporine + albumin infusions ($250–$400/month); avoid steroids.
- •Children (1–6 yrs), *NPHS1* mutation, eGFR >25: Prioritize living-donor transplant ($22,900–$29,200)—superior 5-yr graft survival vs. dialysis.
- •Adolescents with comorbid diabetes/hypertension: Tacrolimus-based regimen ($305–$415/month) + strict BP/lipid control; defer transplant until metabolic stability.
- •Low-budget families (annual income <¥80,000): Peritoneal dialysis ($580/month) + government subsidy-eligible immunosuppressants (cyclosporine at ¥1,200/month = $167).
- •eGFR <10 + recurrent sepsis: Expedited deceased-donor transplant ($27,500–$34,000) — mortality risk exceeds dialysis beyond 6 months.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Congenital Nephrotic Syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Congenital Nephrotic Syndrome treatment with China top medical destinations:
